Our Janssen COVID-19 Vaccine

How It Works

Our COVID-19 vaccine is a monovalent, recombinant, replication incompetent **adenovirus type 26 vectored vaccine**

Our vaccine was developed using Janssen's AdVac® technology.

This technology was also used to develop Janssen's European Commission-approved **Ebola vaccine regimen and construct our HIV, RSV and Zika investigational vaccine candidates.**

We use a piece of DNA that codes for the coronavirus "spike" and place it inside a **non-replicating adenoviral vector. The vaccine cannot cause COVID-19**



Our Clinical Progress

~45,000 participants enrolled in our single-dose Phase 3 ENSEMBLE trial

17 countries have **ongoing Phase 1, 2, 3 trials**

Aiming for **~30,000** participants to be enrolled in our two-dose regimen Phase 3 ENSEMBLE 2 trial

ENSEMBLE Phase 3 topline data demonstrated that the vaccine candidate met **primary endpoints**

Vaccine Manufacturing, Supply and Access



The Company's anticipated manufacturing timeline will enable it to **meet its full year 2021 supply commitments**, including those signed with governments and global organizations

Our vaccine is estimated to remain stable for **two years at -20°C / -4°F** and a maximum of **three months of which can be at temperatures of 2-8° C / 36°–46° F**



Most refrigerators store food at or below **4° C / 40° F** and freezers clock in at or below **-18° C / 0° F**[i]

Transportation and storage of our vaccine is **compatible with standard vaccine storage and distribution channels**

Access to a Vaccine

We aim to **make our vaccine available** on a **not-for-profit** basis for emergency pandemic use



We plan to allocate up to **500 million vaccine doses to lower income countries**

J&J Works in Partnership

Johnson & Johnson is **collaborating to help ensure our research platforms and outbreak expertise can be maximized** to stem this pandemic. We have worked closely with clinical trial investigators and governments around the world, in addition to partnering with the **Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH) and the Beth Israel Deaconess Medical Center (BIDMC).**

For more information on Johnson & Johnson's approach to help combat COVID-19, **visit jnj.com/coronavirus**.

The Janssen COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA) but has been authorized by FDA through an Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) in individuals 18 years of age and older.

The emergency use of this product is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the medical product under Section 564(b)(1) of the FD&C Act, unless the declaration is terminated or authorization revoked sooner.

Please read Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including full EUA Prescribing Information available at www.JanssenCOVID19Vaccine.com/EUA-factsheet.

The COVID-19 vaccine has also been granted a Conditional Marketing Authorization from the European Commission for use in 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstein, and has been issued an Emergency Use Listing by the World Health Organization.

[i] https://www.fda.gov/consumers/consumer-updates/are-you-storing-food-safely

This factsheet has been approved for U.S. use only. For use outside of the U.S., local reviews and approvals in the country must be conducted before use.

Last updated: May 2021